Bio-View Ltd (TA:BIOV) — Market Cap & Net Worth
Market Cap & Net Worth: Bio-View Ltd (BIOV)
Bio-View Ltd (TA:BIOV) has a market capitalization of $20.36 Million (ILA7.60 Billion) as of September 16, 2026. Listed on the TA stock exchange, this Israel-based company holds position #25137 globally and #360 in its home market, demonstrating a -3.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-View Ltd's stock price ILA79.90 by its total outstanding shares 129486329 (129.49 Million). Also see BIOV current and non-current assets for a full breakdown of the balance sheet.
Bio-View Ltd Market Cap History: 2015 to 2026
Bio-View Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.50 Billion to $27.74 Million (-30.63% CAGR). Also see Bio-View Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Bio-View Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-View Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Bio-View Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.40x
Bio-View Ltd's market cap is 0.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.50 Billion | $34.53 Million | $4.07 Million | 43.47x | 369.21x |
| 2016 | $1.28 Billion | $33.29 Million | $4.44 Million | 38.42x | 288.27x |
| 2017 | $1.31 Billion | $27.76 Million | -$1.25 Million | 47.17x | N/A |
| 2018 | $779.00 Million | $25.28 Million | -$1.85 Million | 30.81x | N/A |
| 2019 | $1.05 Billion | $35.79 Million | $2.52 Million | 29.47x | 417.68x |
| 2020 | $1.39 Billion | $25.96 Million | $884.00K | 53.62x | 1574.73x |
| 2021 | $1.13 Billion | $30.51 Million | $2.18 Million | 37.19x | 519.61x |
| 2022 | $1.28 Billion | $29.14 Million | $587.00K | 44.04x | 2186.38x |
| 2023 | $11.39 Million | $34.77 Million | $383.00K | 0.33x | 29.73x |
| 2024 | $10.14 Million | $25.66 Million | -$3.15 Million | 0.40x | N/A |
Competitor Companies of BIOV by Market Capitalization
Companies near Bio-View Ltd in the global market cap rankings as of September 16, 2026. Review Bio-View Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bio-View Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.42 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #232 globally with a market cap of $107.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.42 Billion | $102.03 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.75 |
| #232 | Stryker Corporation | NYSE:SYK | $107.98 Billion | $281.50 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Bio-View Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Bio-View Ltd's market cap moved from $1.50 Billion to $ 27.74 Million, with a yearly change of -30.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA27.74 Million | +378.44% |
| 2025 | ILA5.80 Million | -42.81% |
| 2024 | ILA10.14 Million | -10.98% |
| 2023 | ILA11.39 Million | -99.11% |
| 2022 | ILA1.28 Billion | +13.09% |
| 2021 | ILA1.13 Billion | -18.48% |
| 2020 | ILA1.39 Billion | +31.99% |
| 2019 | ILA1.05 Billion | +35.38% |
| 2018 | ILA779.00 Million | -40.51% |
| 2017 | ILA1.31 Billion | +2.38% |
| 2016 | ILA1.28 Billion | -14.80% |
| 2015 | ILA1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Bio-View Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.36 Million USD |
| MoneyControl | $20.36 Million USD |
| MarketWatch | $20.36 Million USD |
| marketcap.company | $20.36 Million USD |
| Reuters | $20.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more